Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLTP | P55058 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | AGER | Q15109 | 2/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL728966 | 0.93 | PLTP (0.41) | PLTPALDH1A1MAPTHPGDGAA | |
| SCHEMBL727297 | 0.91 | PLTP (0.43) | PLTPALDH1A1MAPTHPGDAGER | |
| SCHEMBL729134 | 0.88 | PLTP (0.38) | PLTPALDH1A1MAPTHPGDAGER | |
| SCHEMBL727478 | 0.87 | MEN1 (0.40) | PLTPALDH1A1MAPTHPGDSPHK1 | |
| SCHEMBL727541 | 0.87 | ALDH1A1 (0.40) | ALDH1A1MAPTHPGDGAARAB9A | |
| SCHEMBL727826 | 0.86 | PLTP (0.37) | PLTPALDH1A1MAPTHPGDAGER | |
| SCHEMBL728882 | 0.86 | PLTP (0.38) | PLTPALDH1A1MAPTHPGDAGER | |
| SCHEMBL727718 | 0.85 | FBP1 (0.43) | PLTP | |
| SCHEMBL729036 | 0.85 | PLTP (0.37) | PLTPALDH1A1MAPTHPGD | |
| SCHEMBL728897 | 0.84 | PLTP (0.36) | PLTPAGERSPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781629-B1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARM CO LTD (KR) | 2015-07-29 | — | — | EP | claimed |
| US-8178688-B2 | Benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2012-05-15 | — | — | US | claimed |
| JP-2011529876-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-8008329-B2 | Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2011-08-30 | — | — | US | claimed |
| EP-2307016-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | Dong Wha Pharmaceutical Co., Ltd. (KR) | 2011-04-13 | — | — | EP | claimed |
| US-20100240890-A1 | Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | DONG WHA PHARMACEUTICAL IND. CO., LTD. | 2010-09-23 | — | — | US | claimed |
| WO-2010013975-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2010-02-04 | — | — | WO | claimed |
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | Dong Wha Pharm, Co. Ltd. (KR) | 2010-02-04 | — | — | US | claimed |
| JP-2008509134-A | — | — | 2008-03-27 | — | — | JP | claimed |
| EP-1781629-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) | 2007-05-09 | — | — | EP | claimed |
| WO-2006014087-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARMACEUTICAL. IND. CO., LTD. (KR) | 2006-02-09 | — | — | WO | claimed |
| EP-1781629-B1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARM CO LTD (KR) | 2015-07-29 | — | — | EP | disclosed |
| US-8178688-B2 | Benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2012-05-15 | — | — | US | disclosed |
| US-8008329-B2 | Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2011-08-30 | — | — | US | disclosed |
| EP-2307016-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | Dong Wha Pharmaceutical Co., Ltd. (KR) | 2011-04-13 | — | — | EP | disclosed |
| US-20100240890-A1 | Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | DONG WHA PHARMACEUTICAL IND. CO., LTD. | 2010-09-23 | — | — | US | disclosed |
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | Dong Wha Pharm, Co. Ltd. (KR) | 2010-02-04 | — | — | US | disclosed |
| WO-2010013975-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240890-A1 | Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | CMA1, IL5, HRH4 | PLTP 2070/4885ALDH1A1 1751/4885MAPT 2826/4885 |
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | SOST, BPGM, PTH1R | PLTP 3704/4885ALDH1A1 3555/4885MAPT 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.